These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22365946)

  • 1. Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure.
    Nishi K; Sato Y; Miyamoto T; Toma M; Taniguchi R; Fukuhara R; Saijo S; Fujiwara H; Takatsu Y
    J Cardiol; 2012 May; 59(3):366-73. PubMed ID: 22365946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infusion therapy at outpatient clinic in chronic end-stage heart failure].
    Nishi K; Sato Y; Miyamoto T; Taniguchi R; Matsuoka T; Kuwabara Y; Isoda K; Yamane K; Hatakenaka T; Fujinaga K; Fujiwara H; Takatsu Y
    J Cardiol; 2007 May; 49(5):251-8. PubMed ID: 17552290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure.
    Bonios MJ; Terrovitis JV; Drakos SG; Katsaros F; Pantsios C; Nanas SN; Kanakakis J; Alexopoulos G; Toumanidis S; Anastasiou-Nana M; Nanas JN
    Int J Cardiol; 2012 Sep; 159(3):225-9. PubMed ID: 21481958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.
    Gorodeski EZ; Chu EC; Reese JR; Shishehbor MH; Hsich E; Starling RC
    Circ Heart Fail; 2009 Jul; 2(4):320-4. PubMed ID: 19808355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure.
    Roffman DS; Applefeld MM; Grove WR; Talesnick BS; Sutton FJ; Newman KA; Reed WP
    Clin Pharm; 1985; 4(2):195-9. PubMed ID: 3987220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure.
    Upadya S; Lee FA; Saldarriaga C; Verma S; Sedrakyan A; Nystrom K; Katz SD
    J Heart Lung Transplant; 2004 Apr; 23(4):466-72. PubMed ID: 15063407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
    Meissner A; Schmelzle T; Simon R
    Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study.
    Elis A; Bental T; Kimchi O; Ravid M; Lishner M
    Clin Pharmacol Ther; 1998 Jun; 63(6):682-5. PubMed ID: 9663183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
    Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
    Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient parenteral inotropic therapy for advanced heart failure.
    Young JB; Moen EK
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial.
    Oliva F; Latini R; Politi A; Staszewsky L; Maggioni AP; Nicolis E; Mauri F
    Am Heart J; 1999 Aug; 138(2 Pt 1):247-53. PubMed ID: 10426835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of intermittent inotropic therapy in unhospitalized patients with refractory heart failure.
    Moga VD; Luca C; Luca CT; Branea H; Drăgulescu SI
    Rom J Intern Med; 1999; 37(1):25-9. PubMed ID: 15523942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial).
    Yancy CW; Singh A
    Am J Cardiol; 2006 Jul; 98(2):226-9. PubMed ID: 16828598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent infusion of inotropes in the outpatient setting: one-year post treatment analysis.
    López-Candales A; Carron C; Graham S; Schwartz J
    P R Health Sci J; 2000 Jun; 19(2):107-14. PubMed ID: 10909705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
    López-Candales AL; Carron C; Schwartz J
    Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.